5th International Symposium on Minimal Residual Cancer
Last Modified: May 11, 2005
Conference Dates: September 11-14, 2005
Conference Location: Fairmont Hotel, San Francisco, CA
Sponsoring Group: International Symposium on Minimal Residual Cancer
Conference Web Page URL: www.ismrc.org
Topics Covered: The Detection of Microscopic Disease in Breast Cancer: a Paradigm for Other Solid Tumors
ICC- and PCR-based strategies
Microscopic disease in sentinel nodes
Microscopic disease in bone marrow: when to detect?
Circulating tumor cells (CTCs): a prognostic or predictive factor?
MRD in bone marrow: future directions:
MRD in blood: future directions
Panel discussion: Cooperation between USA and EU for the development and implementation of methods of detection of MRD in breast cancer
The Detection of Microscopic Disease in Solid Malignancies
MRD in prostate cancer
MRD in NSCLC and GI malignancies
MRD in gynecological cancer
The Biology of MRD: Potential Relevance for Cancer Research Applications
The biology of metastasis in breast cancer: MRD as a model
Combined genome/transcriptosome analysis of single disseminated tumor cells
Genomic profiling and MRD: technology development and future perspectives
Expression signature of MRD in peripheral blood
Expression profiling of CTCs in breast and prostate cancer
Therapeutic targets in MRD
Glycobiology of solid tumors
Circulating endothelial cell analysis
Panel discussion: Single or multiple technologies for determining the biology of MRD
Applications to Clinical Practice
The development of clinical trials evaluating MRD: Challenges and opportunities. The MRC trialists initiative
Conference Objectives: To report on the most relevant advances in the detection and characterization of minimal residual cancer in solid tumors.
Who Should Attend: Cancer researchers and clinicians
Registration Information: Please refer to www.ismrc.org
Conference Fees: $390- academic, $200 - student prior to July 15
Continuing Education: No
Flow Cytometry Indicates Treatment Response in AML
Sep 13, 2012 - For children with acute myeloid leukemia, minimal residual disease activity, as measured using flow cytometry, is a good indicator of treatment response, with morphologic analysis providing limited additional information, according to a study published online Sept. 10 in the Journal of Clinical Oncology.
Blogs and Web Chats
OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.
Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!